|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease显示文摘AIM: To compare the effi cacy and tolerability of S-pan- toprazole (20 mg once a day) versus racemic Panto- prazole (40 mg once a day) in the treatment of gastro- esophageal reflux disease (GERD). METHODS: This multi-centre, randomized, double-blind clinical trial consisted of 369 patients of either sex suf- fering from GERD. Patients were randomly assigned to receive either one tablet (20 mg) of S-pantoprazole once a day (test group) or 40 mg racemic pantoprazole once a day (reference group) for 28 d. Patients were evaluated for reduction in baseline on d 0, GERD symptom score on d 14 and 28, occurrence of any adverse effect during the course of therapy. Gastrointestinal (GI) endoscopy was performed in 54 patients enrolled at one of the study centers at baseline and on d 28. RESULTS: Signifi cant reduction in the scores (mean and median) for heart burn (P < 0.0001), acid regurgitation (P < 0.0001), bloating (P < 0.0001), nausea (P < 0.0001) and dysphagia (P < 0.001) was achieved in both groups on d 14 with further reduction on continuing the therapy till 28 d. There was a statistically signifi cant difference in the proportion of patients showing improvement in acid regurgitation and bloating on d 14 and 28 (P = 0.004 for acid regurgitation; P = 0.03 for bloating) and heart burn on d 28 (P = 0.01) between the two groups, with a higher proportion in the test group than in the refer- ence group. Absolute risk reductions for heartburn/acid regurgitation/bloating were approximately 15% on d 14 and 10% on d 28. The relative risk reductions were 26%-33% on d 14 and 15% on d 28. GI endoscopy showed no signifi cant difference in healing of esophagitis (P = 1) and gastric erosions (P = 0.27) between the two groups. None of the patients in either group reported any adverse effect during the course of therapy.CONCLUSION: In GERD, S-pantoprazole (20 mg) is more effective than racemic pantoprazole (40 mg) in improving symptoms of heartburn, acid regurgitation, bloating and equally effective in healing esophagitis and gastric erosions. The relative risk reduction is 15%-33%. Both drugs are safe and well tolerated. | Vikas G Pai Nitin V Pai Hemant P Thacker Jaisingh K Shinde Vijay P Mandora Subhash S Erram | 2006 | World Journal of Gastroenterology2006，12，37： | 19 |
| 2 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 3 | No difference in mortality among ALPPS,two-staged hepatectomy,and portal vein embolization/ligation:A systematic review by updated traditional and network meta-analyses显示文摘Background:There is an ongoing debate on the feasibility,safety,and oncological efficacy of the associating liver partition and portal vein ligation for staged hepatectomy(ALPPS)technique.The aim of this study was to compare ALPPS,two-staged hepatectomy(TSH),and portal vein embolization(PVE)/ligation(PVL)using updated traditional meta-analysis and network meta-analysis(NMA).Data sources:Electronic databases were used in a systematic literature search.Updated traditional metaanalysis and NMA were performed and compared.Mortality and major morbidity were selected as primary outcomes.Results:Nineteen studies including 1200 patients were selected from the pool of 436 studies.Of these patients,315(31%)and 702(69%)underwent ALPPS and portal vein occlusion(PVO),respectively.Ninetyday mortality based on updated traditional meta-analysis,subgroup analysis of the randomized controlled trials(RCTs),and both Bayesian and frequentist NMA did not demonstrate significant differences between the ALPPS cohort and the PVE,PVL,and TSH cohorts.Moreover,analysis of RCTs did not demonstrate significant differences of major morbidity between the ALPPS and PVO cohorts.The ALPPS cohort demonstrated significantly more favorable outcomes in hypertrophy parameters,time to operation,definitive hepatectomy,and R0 margins rates compared with the PVO cohort.In contrast,1-year disease-free survival was significantly higher in the PVO cohort compared to the ALPPS cohort.Conclusions:This study is the first to use updated traditional meta-analysis and both Bayesian and frequentist NMA and demonstrated no significant differences in 90-day mortality between the ALPPS and other hepatic hypertrophy approaches.Furthermore,two high quality RCTs including 147 patients demonstrated no significant differences in major morbidity between the ALPPS and PVO cohorts. | Paschalis Gavriilidis Robert P Sutcliffe Keith J Roberts Madhava Pai Duncan Spalding Nagy Habib Long R Jiao Mikael H Sodergren | 2020 | Hepatobiliary & Pancreatic Diseases International2020，19，5： | 6 |
| 4 | Risk for esophageal neoplasia in B arrett’s esophagus patients with mucosal changes indefinite for dysplasia显示文摘 | Bela Horvath Prabhdeep Singh Hao Xie Prashanthi N Thota Daniela S Allende Rish K Pai Deepa T Patil Thomas P Plesec John R Goldblum Xiuli Liu | 2015 | J Gastroenterol Hepatol2015，，： | 2 |
| 5 | Risk factors for early myocardial infarction in South Asians compared with individuals in other countries显示文摘 | Joshi P Islam S Pais P | 2007 | JAMA2007，297，3： | 1 |
| 6 | Bioequivalenee evaluation of two omeprazole enteric-coated formulations in humans显示文摘 | Farinha A Biea A Pais J P | 1999 | Eur J Pharm Sci1999，7，4： | 1 |
| 7 | A prospective study of phryngocutaneous fistulas following total laryngectomy显示文摘 | Qureshi SS Chaturvedi P Pai PS | 2005 | J Cancer Res Ther2005，1，1： | 1 |
| 8 | Probabilistic assessment of regional mercury exposure显示文摘 | Seigneur C Pai P Gerath M | 1997 | Water air and soil pollution1997，97，： | 1 |
| 9 | A randomized,placebocontrolled,double-blind trial of ondanse-tron in renal itch显示文摘 | Murphy M Reaich D Pai P | 2003 | Br J Dermatol2003，148，2： | 1 |
| 10 | Steady-state plasma pharmacokinetics of oral voricon- azole in obese adults显示文摘 | PAI M T P | 2011 | Antimicrob Agents Chemother2011，55，6： | 1 |
| 11 | Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators显示文摘 | HO AT PAI SM TIMOTHY P | 2005 | Pacing Clin Electrophysiol2005，28，7： | 1 |
| 12 | The prognosis of latent tuberculosis: can disease be predicted? 显示文摘 | Anderden P Doherty T M Pai M | 2007 | Trends Mol Med2007，13，5： | 1 |
| 13 | A fully nonlinear theory of curved and twisted composite rotor blades accounting for warpings and three-dimensional stress effects显示文摘 | Pai P F Nayfeh A H | 1994 | International Journal for Solids and Structure1994，31，9： | 1 |
| 14 | Antioxidants in dermatology 显示文摘 | Pai VV Shukla P Kikkeri NN | 2014 | Indian Dermatol Online J2014，5，2： | 1 |
| 15 | Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI显示文摘 | Chin C L Tovcimak A E Hradil V P Seifert T R Hollingsworth P R Chandran P Zhu C Z Gauvin D Pai M Wetter J Hsieh G C Honore P Frost J M Dart M J Meyer M D Yao B B Cox B F Fox G B | | 0，，02： | 1 |
| 16 | PLD growth of CuAlO2 显示文摘 | Neumann-Spallart M Pai S P Pinto R | 2007 | Thin Solid Films2007，515，24： | 1 |
| 17 | Fuzzy algorithms for learning vector quantization显示文摘 | N B Karayiannis P I Pai | 1996 | IEEE Trans on Neural Networks1996，7，5： | 1 |
| 18 | Effects acidity and molybdate concentration on the kinetics of the formation of the phosphoantimonylmolybdenum blue complex显示文摘 | PAI S C YANG C C RILEY J P | 1990 | Analytica Chimica1990，229，： | 1 |
| 19 | The prognosis of latent tuberculosis:can disease be predicted显示文摘 | Anderden P Doherty TM Pai M | | 0，，05： | 1 |
| 20 | Relationships between Voltage and Angle Stability of Power Systems显示文摘 | Voumas C D Sauer P W Pai M A | 1996 | International Journal of Electrical Power and Energy System1996，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员